Navigation Links
Vermillion Announces Issuance of Patent for Peripheral Artery Disease
Date:1/11/2011

AUSTIN, Texas, Jan. 11, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,867,719 entitled "Beta-2 microglobulin as a biomarker for peripheral artery disease" to the Company. The patent claims are directed to Beta-2 microglobulin and biomarker combinations that include Beta-2 microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay. The studies underlying the patent were conducted with Dr. John P. Cooke, M.D., Ph.D., a Professor and Associate Director of the Stanford Cardiovascular Institute at Stanford University School of Medicine. Dr. Cooke is a founder and past President of the Society for Vascular Medicine, and an author of over 350 scientific articles in vascular medicine and biology.

"The issuance of this PAD biomarker patent will help our efforts to develop and commercialize our VASCLIR™ test for PAD. We continue to progress our PAD program, including the initiation of our intended use study," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Austin, Texas. Additional information about Vermillion can be found on the Web at www.vermillion.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
2. Vermillion Reports Financial Results for the Third Quarter 2010
3. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
4. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
5. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
6. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
7. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
8. Vermillion Announces the Reappointment of Officers and Confirmation of Director
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
11. Vermillion Files Plan of Reorganization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/9/2017)... and INDIANAPOLIS , June 9, ... living with diabetes. In a further effort to help ... affected by this condition, the International Diabetes Federation (IDF) ... ) have come together for the second phase of ... Systems programme (BRIDGES 2), reaffirming their commitment to helping ...
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI Graph today ... a new, greatly improved version of the Doctor Referral teaming dataset commonly available from ... and subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” ...
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or ... But how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional ... early symptoms of AMD? A study published recently in Dove Medical Press ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal ... prefer to read it, and some people don't like it at all. FindaTopDoc took ... they found: , Erotic literature can give readers a taste of their deepest, darkest ...
Breaking Medicine News(10 mins):